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rcute coronary syndromes (ACS) account for approxi-
ately 1.6 million annual inpatient hospital discharges in
he U.S. (1). Approximately 80% of these are due to
on–ST-segment elevations ACS (NSTE-ACS). In this
ear’s review, we highlight publications and presentations
etween May 2006 and April 2007 in 6 areas: risk assess-
ent, antithrombotic therapy, anti-ischemic therapy, per-
utaneous coronary intervention (PCI), lipid management,
nd selected patient subgroups.
isk Assessment
lthough several risk scores that predict short-term out-
omes have been developed and validated, research in the
ast year has focused on the assessment of risk at the time
f discharge and on longer-term prediction of outcome. The
RACE (see Table 1 for clinical trial acronyms) hospital
ischarge risk score incorporates 9 historical and clinical
ariables, and was demonstrated to predict mortality at 6
onths to 4 years with accuracy (c-statistics 0.76 to 0.80)
2). Modifications of the score (Otago-Southland model)
2) and a simplified GRACE risk calculator (3) provide
urther refinements to predict long-term mortality and the
omposite of death or myocardial infarction (MI), respec-
ively. Future models may need to incorporate more infor-
ation regarding disease in noncoronary vascular beds (e.g.,
erebrovascular [4], peripheral arterial [4], and systemic
rterial [5]), because patients with disease in these territories
lso are at increased risk for late cardiovascular events. Such
isk scores are important, because patients with NSTE-
CS continue to experience higher mortality than patients
ith ST-segment elevation myocardial infarction (STEMI)
or up to 10 years (6), and risk stratification at hospital
ischarge may be very useful in guiding post-discharge
anagement in such patients.
New data on depression in patients with ACS described
n 18% prevalence of moderate/severe depressive symptoms
of which only 25% of cases had documented recognition of
epressive symptoms in the medical record) (7). Elderly
rom the TIMI Study Group, Division of Cardiovascular Medicine, Department of
edicine, Brigham and Women’s Hospital and Harvard Medical School, Boston,(
assachusetts. Author disclosures are listed at the end of this paper.
Manuscript received April 23, 2007; accepted May 14, 2007.atients and those who live alone were at highest risk for
epression (8), and these patients were the most likely to
uffer the adverse consequences of depression, such as
oncompliance to proven therapies (9) and delayed return to
ork (10).
iomarkers. A new model of risk stratification based on a
anel of molecular and genetic factors is shown in Figure 1
11). As the investigation of novel biomarkers (especially
irculating serum and plasma markers) continues to accelerate,
uch a construct helps to organize the various classes of
iomarkers and highlights their role in the pathogenesis of
CS. To evaluate the clinical utility of new biomarkers
12–23), 3 fundamental questions have been proposed by
orrow and de Lemos (24) to serve as benchmarks (Table 2).
. Can the clinician measure the biomarker?
. Does the biomarker add new information?
. Will it help the clinician manage patients?
ne of the most promising novel markers is growth
ifferentiation factor (GDF)-15, a member of the trans-
orming growth factor-beta cytokine superfamily. Growth
ifferentiation factor-15 is released from cardiomyocytes
fter ischemia and reperfusion injury. Circulating serum
evels of GDF-15 were shown to be a strong independent
arker of 1-year mortality (Fig. 2), providing additional
rognostic information beyond that attained by existing
iomarkers and clinical features of patients with NSTE-
CS (12). Further characterization of GDF-15 along with
mproved understanding of the role it may play in the
athogenesis of ACS is needed before GDF-15 joins other
stablished biomarkers such as troponin (25), B-type natri-
retic peptide (BNP) (25,26), C-reactive protein (27),
T-segment depression (28), and alterations in myocardial
erfusion (29).
Other promising biomarkers with new data are sum-
arized in Table 2 and include new markers of ischemia/
ecrosis, inflammatory/metabolic status, lymphocyte sub-
ets, modulators of atherothrombosis, and markers of
ntracellular signaling. Additional research evaluating the
elevant value of novel biomarkers to predict initial ACS
30) and recurrent ACS events (31) are needed.
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lopidogrel, in addition to aspirin, is now considered to
e part of the standard antithrombotic regimen for all
atients with NSTE-ACS who do not have a contrain-
ication (e.g., active bleeding) (32). However, limitations
o the clinical effectiveness of clopidogrel include a
elayed onset of action after the standard 300-mg loading
ose and inter- and intrapatient variability in antiplatelet
ffect (so-called “clopidogrel response variability”) (33),
oth of which have been associated with recurrent
schemic complications. To overcome these limitations,
nvestigators have explored loading doses 300 mg in
Figure 1 Panel of Cellular and Molecular Components Involved
ACS  acute coronary syndrome; EPC  endothelial progenitor cell; FLAP  5-lipo
MMP  matrix metalloproteinase; MPO  myeloperoxidase; PAI-1  plasminogen
ble CD40 ligand; TNF  tumor necrosis factor; VEGF  vascular endothelial growt
Clinical Trial Acronyms
Table 1 Clinical Trial Acronyms
ACUITY Acute Catheterization and Urgent Inter
ANTHEM Anticoagulation With rNAPc2 to Help E
ARMYDA Antiplatelet Therapy for Reduction of M
CHARISMA Clopidogrel for High Atherothrombotic
CRUSADE Can Rapid Risk Stratification of Unstab
Implementation of the ACC/AHA Gu
ELISA Early or Late Intervention in Unstable A
FRISC Fast Revascularization During Instabilit
GRACE Global Registry of Acute Coronary Even
GUSTO Global Utilization of Streptokinase and
ICTUS Invasive Versus Conservative Treatmen
MERLIN Metabolic Efficiency With Ranolazine fo
Syndromes
MIRACL Myocardial Ischemia Reduction With A
PROTECT Randomized Trial to Evaluate the Relat
Post-PCI Ischemia Among Antiplatel
PROVE IT Pravastatin or Atorvastatin Evaluation
SYNERGY Superior Yield of the New Strategy of E
TIMI Thrombolysis In Myocardial Infarction
TRITON Trial to Assess Improvement in Therap
ACC/AHA  American College of Cardiology/American Heart Associa
intervention; rNAPc2  recombinant nematode anticoagulant proteinatients with NSTE-ACS and have observed a more
apid onset of action, a higher level of platelet inhibition,
nd a greater reduction in platelet activation with 600 mg
ompared with 300 mg (34,35), with only modest further
ncremental benefit after a 900-mg load (34).
Prasugrel is a novel thienopyridine with greater potency,
aster onset of action, and more consistent inhibition of
latelet aggregation than even 600-mg clopidogrel (36). It is
eing studied in the phase III clinical trial TRITON–TIMI
8, an event-driven study that has completed enrollment of
ver 13,600 patients with ACS undergoing PCI, which will
e reported during the next year (37).
e Pathogenesis of Acute Coronary Syndrome
se–activating protein pathway; IL  interleukin; LTA4  leukotriene A4 pathway;
tor inhibitor; PAPP-A  pregnancy-associated plasma protein A; sCD40L  solu-
r; vWF  von Willebrand factor. Adapted from Anwaruddin et al. (11).
Triage Strategy
te MACE
ial Damage During Angioplasty
nd Ischemic Stabilization, Management, and Avoidance
ina Patients Suppress Adverse Outcomes With Early
s
ronary Artery Disease
r Occluded Arteries
stable Coronary Syndromes
Ischemia in NonST-Segment Elevation Acute Coronary
ive Cholesterol Lowering
OTECTion Against Post-PCI Microvascular Dysfunction and
Antithrombotic Agents
ection Therapy
arin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors
utcomes by Optimizing Platelet Inhibition With Prasugrel
ACE  major adverse cardiac events; PCI  percutaneous coronary
 tissue plasminogen activator.in th
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Year in Non–ST-Segment Elevation ACS October 2, 2007:1386–95An alternative method to increase the inhibition of
latelet function is to add a third agent to the standard
ombination of aspirin and clopidogrel. The ELISA-2 trial
ompared the effect of adding the glycoprotein (GP) IIb/
IIa receptor antagonist tirofiban (so-called “triple antiplate-
et therapy”) to standard dual therapy in patients with
STE-ACS treated with an early invasive approach and
ound a trend toward less (166 IU/l vs. 192 IU/l; p  0.2)
actate dehydrogenase release over 48 h, and fewer (46% vs.
7%; p  0.052) infarcts with triple therapy (38).
The final results of the ACUITY trial, a trial of 13,819
atients with NSTE-ACS managed with an early invasive
trategy, were published in 2006. The ACUITY trial
andomized patients to 1 of 3 antithrombotic regimens:
) bivalirudin monotherapy; 2) bivalirudin  a GP IIb/IIIa
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Figure 2 Tertiles of GDF-15 at Baseline and Follow-Up Predict
Mortality in Non–ST-Segment Elevation Acute Coronar
Patients enrolled in the GUSTO IV-ACS trial were stratified according to tertiles of g
after randomization. Mortality at 1 year was highest for the patients in the upper t
(12).
Novel Biomarkers
Table 2 Novel Biomarkers
Ischemia/necrosis markers
Heart-type fatty acid binding protein (13)
Ischemia-modified albumin (14)
Inflammatory/metabolic markers
Growth differentiation factor-15 (12)
C-reactive protein gene polymorphisms (15)
Adiponectin (16)
Lymphocyte subsets
CD4CD28null (17)
CD4CD25 (18)
Modulators of thrombosis
Lipoprotein-associated phospholipase A2 (19)
Myeloperoxidase (20)
Matrix metalloproteinase-3 polymorphism (21)
Markers of intracellular signaling
Platelet collagen receptor glycoprotein VI (22)
Soluble intercellular adhesion molecule-1 (23)
  preliminary;   modest supportive data;   multiple s
unknown.eceptor antagonist; or 3) heparin  a GP IIb/IIIa antag-
nist (39). The principal findings were that bivalirudin
onotherapy reduced the net clinical composite of
leeding  ischemic complications compared with either of
he 2 arms that included a GP IIb/IIIa receptor antagonist
nd that this difference was driven by a markedly lower rate
f bleeding when routine GP IIb/IIIa blockers were not
iven. There were similar rates of ischemic complications
hrough 1 year across the 3 arms (40). The combination of
ivalirudin  GP IIb/IIIa inhibitor did not appear to offer
ny substantial advantage over the other regimens. The
ptimal timing of GP IIb/IIIa inhibitor use also was
valuated in the ACUITY Timing trial (41), which dem-
nstrated that a strategy of initiating GP IIb/IIIa inhibitor
herapy in the catheterization laboratory (i.e., “down-
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1,800 ng/dl) of GDF-15 measured at all time points. Data from Wollert et al.
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October 2, 2007:1386–95 Year in Non–ST-Segment Elevation ACStream”) compared with upstream initiation (i.e., on initial
resentation) an average of 4 h earlier was associated with a
0% reduction in bleeding (p  0.009). However, patients
andomized to downstream initiation tended to experience
ore ischemic complications (7.9% vs. 7.1%; p  0.13). Of
ote, the average time from hospital arrival to PCI in the
RUSADE registry was approximately 24 h (42), and the
elay is even longer for patients who are admitted on
eekends (43). An ongoing trial (EARLY-ACS [44]) is
omparing early versus deferred GP IIb/IIIa blockade in
atients with a longer duration of upstream therapy that
ore closely reflects the median delay to catheterization in
he U.S.
The PROTECT–TIMI 30 trial (29) also compared
ivalirudin monotherapy with heparin  GP IIb/IIIa re-
eptor antagonist (eptifibatide) and revealed a similar trade-
ff between a decrease in bleeding and an increase in
schemic complications when bivalirudin without a GP
Ib/IIIa blocker is substituted for the standard regimen of
eparin  GP IIb/IIIa receptor antagonist (Fig. 3). How-
ver, the ACUITY and PROTECT–TIMI 30 trials dif-
ered in the direction of the absolute net benefit (defined as
he MI rate minus the TIMI major bleeding rate), with
he net benefit favoring bivalirudin monotherapy in the
CUITY trial (39) but favoring heparin  GP IIb/IIIa
ntagonist in the PROTECT–TIMI 30 trial (29). Based on
hese findings, an individualized approach that considers
he patient’s risk of bleeding and ischemic complications
n the light of other clinical features, such as the use and
iming of other adjunctive therapies (e.g., clopidogrel,
CI), to determine the optimal antithrombotic regimen
ppears most reasonable.
-4 -3 -2 -1 0 1 2 3
0.5
1.90.7
1.0
0.5
1.2
TIMI Major Bleeding
TIMI Major Bleeding MI
MI
Net Benefit
Net Benefit
Favors Bivalirudin Favors heparin + GP IIb/IIIa
ACUITY:
PROTECT – TIMI 30:
∆ Event Rate (%)
Figure 3 Trade-Off of Efficacy and Safety
in the ACUITY and PROTECT–TIMI 30 Trials
The absolute difference in the rates of myocardial infarction and TIMI major
hemorrhage are shown for each trial, as well as the composite (myocardial
infarction [MI] minus TIMI major bleeding). In the ACUITY trial (n  13,819),
there were more TIMI major hemorrhages prevented with bivalirudin than there
were MIs prevented by heparin  glycoprotein (GP) IIb/IIIa inhibitor, and thus
the net benefit (0.5%) favored bivalirudin. In the PROTECT–TIMI 30 trial
(n  857), the net benefit went in the opposite direction, favoring heparin 
GP IIb/IIIa inhibitor by 1.2%. Data from Gibson et al. (29) and Stone et al. (39).pThe safety of oral antiplatelet therapy was reported in 2
igh-risk subgroups of patients with ACS: those undergo-
ng coronary artery bypass graft (CABG) surgery and those
ith cancer. The CRUSADE trial investigators reported
hat current guideline recommendations (32) to delay
ABG surgery for at least 5 days after the last dose of
lopidogrel generally are not followed, despite demonstrat-
ng that CABG surgery within 5 days of clopidogrel is
ssociated with increased rates of red cell (65% vs. 57%),
arge quantity (4 U) (28% vs. 18%), and platelet (34% vs.
0%) transfusions (45). Meanwhile, a single-center review
f patients with cancer who developed ACS demonstrated
he efficacy and safety of aspirin, whether or not thrombo-
ytopenia was present (46).
A prespecified subgroup analysis examining the efficacy
nd safety of extended clopidogrel (median 28 months) in
he CHARISMA trial demonstrated that patients with a
ocumented prior MI had a 23% reduction (p  0.031) in
ardiovascular death, MI, or stroke compared with placebo,
ith no increase in severe bleeding (47). These findings,
oupled with the latest recommendations to administer at
east 12 months of clopidogrel after implantation of drug-
luting stents (DES) (48), are likely to extend the duration
f clopidogrel that clinicians recommend to patients with
STE-ACS.
The safety and efficacy of rNAPc2, a proximal inhibitor
f the coagulation cascade that targets the tissue factor/
actor VIIa complex, were studied in the phase II AN-
HEM–TIMI 32 trial (49) of moderate-high risk patients
ith NSTE-ACS managed with an early invasive strategy
nd standard antithrombotics (aspirin, heparin or enoxapa-
in, clopidogrel, and GP IIb/IIIa antagonists). Doses of
7.5 g/kg rNAPc2 administered intravenously every 48 h
uring hospitalization reduced new thrombin generation
nd ischemia on ambulatory electrocardiography, suggesting
link between the proximal target of this drug and recurrent
schemia that follows plaque rupture.
Detailed analyses of the nonrandomized subgroups of
atients undergoing post-randomization PCI were reported
or the SYNERGY (50) and ACUITY (41) trials. In the
ormer, enoxaparin was as efficacious (no difference in death
r MI) as unfractionated heparin (UFH) but was associated
ith more bleeding (3.7% vs. 2.5%; p  0.028). In the
atter, bivalirudin was associated with less bleeding than
eparin  GP IIb/IIIa blocker (3% absolute reduction; p 
.0001), with a similar rate of ischemic complications (9%
s. 8%; p  0.48).
leeding. Further efforts to minimize bleeding complica-
ions were identified in subsequent analyses from the
YNERGY and PROTECT–TIMI 30 trials. Patients
reated consistently with enoxaparin in the SYNERGY trial
i.e., no crossing over between UFH and enoxaparin either
efore or after randomization) had a significantly lower
ncidence of death or MI at 30 days (adjusted p  0.041)
ut a trend toward increased bleeding compared with
atients randomized to UFH (51). In the PROTECT–
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Year in Non–ST-Segment Elevation ACS October 2, 2007:1386–95IMI 30 trial, a reduced creatinine clearance (CrCl) was
trongly associated with bleeding (52). Among patients with
rCl 50 ml/min, 45% did not have the proper downward
djustment of the infusion of eptifibatide (from 2 g/kg/
in to 1 g/kg/min), and these patients had a 20% rate of
leeding compared with 0% for patients with proper down-
itration of the infusion. Because several analyses have
hown a correlation between bleeding and increased mor-
ality (53), clinicians should routinely incorporate steps to
inimize bleeding, such as dose adjustment of renally
leared antithrombins as determined by renal function
ssessed at admission and periodically thereafter.
A promising approach to limit bleeding that is in very
arly stages of development involves the use of aptamers,
.e., single-stranded nucleic acids that adopt a specific shape,
nabling high-affinity binding and specificity to target
roteins. Dyke et al. (54) reported phase I results in healthy
olunteers with a protein-binding oligonucleotide to factor
Xa and its complementary antidote. Future clinical use of
uch anticoagulants with desirable pharmacologic features,
ncluding high selectivity, ease of titration, rapid onset/
ffset, and ready reversibility, could lead to a substantial
eduction in bleeding complications.
nti-Ischemic Therapy
anolazine is a novel antianginal agent that inhibits the late
odium current in myocardial cells, thereby reducing some
f the deleterious effects attributed to the overload of
ntracellular sodium and calcium during ischemia. This drug
as studied in 6,560 patients within 48 h of NSTE-ACS
ho were followed for a median of 348 days in the
ERLIN–TIMI 36 trial (55). The addition of ranolazine
o standard ACS therapies did not reduce the primary
omposite of cardiovascular death, MI, or recurrent
schemia, because ranolazine had no effect on death or MI.
owever, ranolazine did reduce recurrent ischemia by 13%
p  0.03) and appeared to be safe, thus providing further
vidence to support its current indication as an antianginal
gent.
nterventional Cardiology in NSTE-ACS
See also Dixon et al. [56].) The use of an early invasive
herapy (catheterization within 48 h of admission) in
STE-ACS has increased (from 53% to 61% in the
RUSADE registry [57]) over the 3 years since the class Ia
ecommendation given by the 2002 American College of
ardiology/American Heart Association guideline update
32). This trend is likely to continue, given the preponder-
nce of positive data favoring an early invasive approach in
STE-ACS that were reported during the past year. The
ost recent meta-analysis confined to patients in the stent
nd GP IIb/IIIa antagonist era (58) compared an early
nvasive strategy with a more conservative approach and
oncluded that the former reduced all-cause mortality by
5% and nonfatal reinfarction by 17% at 2 years. Five-year aata from the FRISC-II trial (59) were directionally similar,
lthough the relative reduction in mortality was more
odest (5%; p  NS) and the benefit of an early invasive
herapy in that trial was most evident in men, nonsmokers,
nd patients with at least 2 risk factors. Furthermore, in a
etrospective propensity-matched analysis, multivessel
tenting was associated with a 20% reduction in ischemic
omplications compared with stenting of only the culprit
essel (60).
A report on the long-term (3- to 4-year) outcomes in the
CTUS trial (61), a Dutch study which compared an early
nvasive with a selective invasive treatment strategy, does
ot support an early invasive approach in all patients. The
atter was, in fact, associated with a trend toward higher
ates of the composite of death, recurrent MI, or rehospi-
alization for angina at 3 years (hazard ratio [HR] 1.21; p
.09) driven by higher rates of MI, largely PCI-induced
elease of biomarkers (HR 1.61; p  0.002), although rates
f all-cause and cardiovascular mortality at 4 years were
imilar between the 2 strategies. Potential explanations for
he findings in the ICTUS study include a liberal definition
f periprocedural MI that led to a higher early event rate
ith the early invasive strategy, a relatively high rate (40%)
f predischarge revascularization in the comparator arm
ith a narrowing of the difference in revascularization rates
etween strategies with time (i.e., a higher rate of cross-
vers), and frequent use of high-intensity lipid-lowering
egimens (62).
The optimal type of stent (DES vs. bare-metal stents) in
atients with NSTE-ACS remains controversial. Implan-
ation of DES appears to reduce periprocedural markers of
nflammation and necrosis (63) and to reduce restenosis.
owever, their use in patients with NSTE-ACS is consid-
red to be “off-label,” because most DES trials have focused
n patients with stable coronary artery disease (CAD).
iven the limited data with DES in patients with NSTE-
CS, and the observation that “off-label” use of DES is
ssociated with increased risk of stent thrombosis (64), we
o not endorse the widespread use of DES in patients with
STE-ACS until additional data are available. Of note, to
educe the risk of late stent thrombosis, patients should be
nstructed to continue dual antiplatelet therapy for at least 1
ear, without interruption, after DES implantation (48).
tatins
tatins are among the most thoroughly studied drugs and
ave a very favorable risk-benefit relationship. A systematic
verview of 74,102 patients enrolled in 35 randomized
lacebo-controlled clinical trials across a wide range of
opulations concluded that statins (excluding cerivastatin,
hich is no longer available) were associated with an excess
f elevated transaminases (4.2  1.7 per thousand; p 
.01) but no significant differences in myalgias, creatine
inase elevation, rhabdomyolysis, or discontinuation due to
ny adverse event (65). This mild increase in the risk of
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October 2, 2007:1386–95 Year in Non–ST-Segment Elevation ACStransaminitis” is outweighed by a reduction in cardiovas-
ular events that begins to appear after 4 months after ACS
Fig. 4) and in cardiovascular mortality at 2 years (66).
lthough the mechanism of early benefit with intensive
tatin treatment (regimens achieving 40% reduction in
ow-density lipoprotein [LDL]) remains incompletely un-
erstood, reductions in tumor necrosis factor- alpha and
nterferon-gamma production in stimulated T lymphocytes
2 h after treatment with 20 mg rosuvastatin in patients
ith ACS suggest that rapid immunomodulation may play
n important role (67).
The results of one important trial of intensive statin
herapy in patients with NSTE-ACS who were undergoing
arly PCI, the ARMYDA study, were published after the
reviously described meta-analysis (68). That trial com-
ared 80-mg atorvastatin 12 h before PCI followed by
nother 40 mg preprocedure with placebo. All patients
eceived a 600-mg loading dose of clopidogrel and were
reated with 40-mg atorvastatin daily after PCI. The 30-day
omposite of death, MI, or unplanned revascularization was
educed from 17% to 5% (p  0.01) in patients receiving
re-PCI atorvastatin; this difference was attributed mostly
o a reduction in MI (15% vs. 5%; p  0.04). This benefit
f short-term pretreatment with high-dose atorvastatin in
atients with NSTE-ACS undergoing PCI suggests the
resence of a non–LDL-mediated early benefit of high-dose
tatin.
Intensive statin therapy with 80 mg atorvastatin was also
ore effective than standard-dose statin (40 mg pravastatin)
n reducing the risk of hospitalization for heart failure (HR
.55; p  0.008) in patients after ACS enrolled in the
ROVE IT–TIMI 22 trial (69). The benefit was indepen-
ent of recurrent MI or a history of heart failure and was
articularly prominent in patients with an elevation of
HR (95% Cl)
1.02 (0.95-1.09)
0.84 (0.72-1.02)
0.76 (0.70-0.84)
0.80 (0.76-0.84)
0.81 (0.77-0.87)
0.84 (0.76-0.94)
Hazard Ratio (95% CI) of Any Cardiovascular Event
1 Month
Pooled
4 Months
6 Months
12 Months
24 Months
1.41.20.830.71
Figure 4 Meta-Analysis of Early
Intensive Statin Therapy in ACS
By 4 months, the use of an early intensive statin (compared with placebo or
low-dose statin control) reduced the risk of overall cardiovascular events in this
analysis of 17,963 patients within 14 days of hospitalization for acute coro-
nary syndrome (ACS) among 13 trials. Estimates to the left of the line of unity
favor intensive statin therapy and those to the right favor the control (either
placebo or low-dose statin). CI  confidence interval; HR  hazard ratio. Data
from Hulten et al. (66).irculating BNP. The mechanism of benefit remains inexplained, although data continue to accrue regarding
o called “pleiotropic” effects of high-dose statins, such as
he favorable effects on C-reactive protein (27) and
itamin D (70).
An evaluation of current treatment guidelines in patients
nrolled in a recent clinical trial suggests that nearly two-
hirds of patients admitted with ACS who had an indication
or statin therapy before the development of the ACS were,
n fact, not treated before admission (71). Even after
nitiation of therapy, poor adherence to statin therapy
emains a challenge, and patients who miss their statin dose
requently appear to be at increased risk for mortality with a
ose-response adherence-mortality relationship that is even
tronger than that observed with beta-blockers (72).
pecific Patient Subgroups
omen. Gender-based differences in cardiovascular dis-
ases long have been recognized, and in the past year an
pdated evidence-based guideline for primary and second-
ry prevention of cardiovascular disease in women was
eleased (73). Among the gender-based differences de-
cribed in that guideline are: 1) a narrower role for aspirin
n primary prevention of coronary events in women than
n men; 2) recognition of the underestimation of risk in
omen whose calculated Framingham global risk score is
n the low or moderate ranges (74); 3) contraindication of
ertain drugs (statins, angiotensin-converting enzyme in-
ibitors, angiotensin receptor blockers) during pregnancy/
actation; and 4) identification of pre-eclampsia/eclampsia
s a risk factor for the development of cardiovascular disease.
The need for a guideline dedicated to women is easily
ustified, because substantial gender differences in ACS have
een observed. Women and men have different cardiac risk
actors (high-density lipoprotein and C-reactive protein are
articularly important coronary heart disease risk factors in
omen [75]), presenting symptoms (e.g., women are more
ikely to experience nausea and less likely diaphoresis [76]),
nd cardiovascular history (women are less likely to have had
rior MI or revascularization [77]). Women with chest pain
re more likely than men to have nonobstructive CAD at
atheterization (78), and these women require fewer proce-
ures and rehospitalizations than women with obstructive
AD (79). However, because nonobstructive CAD requires
ore intensive anti-ischemic drug therapy, the average
ifetime cost estimates for women with nonobstructive
AD is nearly equal to that of women with obstructive
-vessel CAD (79). Finally, compared with men, women
ith NSTE-ACS are at increased risk for bleeding, in part
wing to lower CrCl (women tend to be older and lighter
han men) which results in more frequent excessive dosing
f antithrombotic agents (80). Because recent analyses in
atients with NSTE-ACS demonstrated a strong, consis-
ent, temporal, and dose-related association between bleed-
ng and death (81), proper dose adjustment of antithrom-
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isorders of glucose metabolism. Several observations
ver the past year highlight the importance of abnormal
lucose metabolism in association with NSTE-ACS and
dentify opportunities to improve care. Nearly one-third of
iabetic patients do not have a hemoglobin A1C assessed
uring hospitalization. When assessed, 60% of diabetics
ith ACS were found to have suboptimal control (hemo-
lobin A1C 7.0%) (82). Diabetics with higher baseline
lasma glucose levels have more severe platelet dysfunction,
hich can be reversed by acute aggressive glycemic control
ith intravenous insulin (83). Unfortunately, diabetics also
re less likely to achieve goal levels of LDL and C-reactive
rotein (84), which may indicate the need for more inten-
ive treatments to reduce the risk of subsequent events. One
pproach to accomplish this would be a higher maintenance
ose of clopidogrel (150 mg daily) (85). However, the effect
f this higher dose of clopidogrel, when given for prolonged
eriods, on the risk of bleeding remains to be defined.
Milder forms of impaired glucose metabolism are com-
on in NSTE-ACS and are associated with an increased
isk. Metabolic syndrome was present in 25% of patients
ith ACS in a comprehensive survey conducted in Israel
nd carried a 2-fold increased risk in 1-year mortality even
fter multivariate adjustment (86). Hyperglycemia at pre-
entation, as measured by a random glucose measurement,
as associated with an adverse biomarker panel (higher
roponin and BNP) and increased mortality at 10 months
87).
lderly. Elderly patients with NSTE-ACS tend more
ften to be female and have a higher risk profile (88).
nternational variation exists in the management provided
o the elderly with NSTE-ACS, particularly with regard to
he use of cardiac catheterization and subsequent revascu-
arization (88). Although the risks of most treatments in the
lderly are increased, so are the potential benefits. For
xample, elderly patients (70 years) who achieved the
ptional LDL goal of 70 mg/dl after ACS experienced an
% absolute and 40% relative lower risk of events, reduc-
ions substantially greater than those observed in younger
atients (89). Data from the MIRACL study in patients 24
o 96 h after ACS confirmed the lack of an age-treatment
nteraction among older (65 years of age) versus younger
atients who were randomized to 80-mg/day atorvastatin
ersus placebo, and the safety of 80-mg/day atorvastatin was
imilar between the 2 age groups (90). Further research to
nderstand the reasons for underuse of proven therapies in
he elderly and to define more precisely the risk-benefit
elationship is necessary.
uality Improvement
number of efforts are ongoing to improve the quality of
are delivered to patients with NSTE-ACS. The CRUSADE
egistry collected data from165,000 patients with NSTE- ACS admitted to 400 U.S. hospitals (91) and now has
erged with the National Registry for Myocardial Infarc-
ion. Hospitals previously participating in these registries
ill now report to the National Cardiovascular Data Reg-
stry under the auspices of the American College of Cardi-
logy. On a more global front, the GRACE registry (92)
ontinues to collect important data reflecting worldwide
ractice and outcomes in NSTE-ACS. Real-time monitor-
ng of key quality indicators represents a new advance in
uality improvement. Use of a system that reviews and
mplements key quality-of-care indicators in real time in the
ospital has resulted in greater use of evidence-based ther-
pies that improved outcomes more rapidly than the tradi-
ional annual cycle of quality improvement (93).
Data from the CRUSADE (94) and GRACE (95)
egistries demonstrate that, unfortunately, patients with
STE-ACS at highest risk are least likely to receive
uideline-recommended therapies, even after exclusion of
hose patients with contraindications for proven therapies.
eanwhile, use of complementary and alternative medica-
ions that are not evidence based are increasingly prevalent
n patients with ACS after hospital discharge and, in
articular, are more common in high-risk subgroups of
atients, including minorities, the uninsured, the econom-
cally disadvantaged, and patients with depression (96).
ovel approaches to deliver more evidence-based therapies
o these patients and others with ACS who are most likely
o benefit are needed.
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